X hits on this document

49 views

0 shares

0 downloads

0 comments

7 / 13

Fig2

Y EA R 2001

OTHERS, 15%

CVS, 8%

DIABETES, 3%

ANTI INF., 24%

RESP., 10%

CNS, 5%

GI, 12%

NUTRA., 14%

NSAIDS, 9%

OTHERS DIABETES RESP. CNS NSA IDS NUTRA . GI A NTI INF. CV S

CVS, 18%

ANTI INF., 16%

GI, 13%

DIABETES, 3%

RESP.

RESP., 7%

CNS

CNS, 8%

NSAIDS

NUTRA.

NSAIDS, 11%

GI

YEAR 2010 estimated

NUTRA., 12%

ANTI INF. CVS

OTHERS, 12%

OTHERS DIABETES

Source:ORG MARG Retail Audit 2002

Figure 2 presents market share of top therapeutic segment in the year 2001 with projection made for year 2010.However product choice will depend largely on the internal capabilities of the companies. Here it is very much evident from this projection that lots of opportunities lies with chronic therapy segment however growth is initially slow but it may generate good revenue in long run.

Document info
Document views49
Page views49
Page last viewedSun Jan 22 04:28:34 UTC 2017
Pages13
Paragraphs196
Words3752

Comments